# Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.

> **NCT07243002** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 3000 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07243002
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-15
- **Primary completion:** 2030-05-30
- **Final completion:** 2030-05-30
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07243002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07243002, "Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07243002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*